US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Stage

0.3754

+0.0000

Volume:- -

Turnover:- -

Market Cap:10.85M

PE:-0.11

High:0.3754

Open:0.3754

Low:0.3754

Close:0.3754

Loading ...

Overview Company News Filings

4 Cryptos Community Sentiment for a 10x in April: DeFi and Tech Innovations Take Center Stage

Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients

Press Release: Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D

VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug

Goldman Sachs’ (GS) Adaptability and Core Strengths Set the Stage for Sustained Growth

Jeffs’ Brands Announces Completion of Development Stage for Fort’s AI-Based Pest Control App

Senate Vote Sets Stage for President Trump to Sign Bill Ending IRS DeFi Broker Rule

Social Security says some applicants are exempt from in-person office visits

Nvidia's CPO Reveal Sets Stage for Wave of Optical Tech Announcements

A New Chapter Awaits – Take Centre Stage in F1® 25; An Epic Formula 1® Blockbuster

SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study

Palestinians Stage Rare Protest Against Hamas in Gaza -- WSJ

Ripple to Retain $75 Million From SEC As the XRP Lawsuit Enters Final Stage

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Can-Fite BioPharma Begins Late-Stage Study of Prospective Psoriasis Medication

MT Newswires Live

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SSI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SSI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","market":"US","secType":"STK","nameCN":"Stage","latestPrice":0.3754,"timestamp":1588968000000,"preClose":0.3754,"halted":3,"volume":0,"delay":0,"floatShares":20307519,"shares":28911336,"eps":-3.332056,"marketStatus":"Halted","change":0,"latestTime":"03-27 19:42:18 EDT","open":0.3754,"high":0.3754,"low":0.3754,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.332056,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743120000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":998884800000,"exchange":"NYSE","adjPreClose":0.3754,"dividendRate":0.133191,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","floatShares":20307519,"roa":"-3.54%","roe":"-44.60%","lyrEps":-3.1264,"shares":28911336,"dividePrice":0.05,"high":0.3754,"amplitude":0,"preClose":0.3754,"low":0.3754,"week52Low":0.27,"pbRate":"0.07","week52High":9.5,"institutionHeld":0.5253,"latestPrice":0.3754,"eps":-3.332056,"divideRate":0.133191,"volume":0,"delay":0,"ttmEps":-3.332056,"open":0.3754,"prevYearClose":8.12},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SSI\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522455624","title":"4 Cryptos Community Sentiment for a 10x in April: DeFi and Tech Innovations Take Center Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2522455624","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522455624?lang=en_us&edition=fundamental","pubTime":"2025-03-28 06:49","pubTimestamp":1743115763,"startTime":"0","endTime":"0","summary":"Jupiter strengthens Solana’s liquidity infrastructure with new DeFi tools.Ondo DAO enhances governance, giving ONDO holders decision-making power.Kaspa’s GHOSTDAG protocol boosts blockchain speed and efficiency.Jupiter establishes new DeFi trading possibilities on the Solana network and Ondo DAO distributes authority control to its user base. Through JasmyCoin users can protect their data while blockchain interacts with IoT devices at the same time Kaspa establishes new speed records through its GHOSTDAG protocol. Cryptos technology advances through these developments which make blockchain systems both scalable and efficient and more accessible to users than previous versions.Kaspa leverages the GHOSTDAG protocol to enhance blockchain efficiency. Unlike conventional proof-of-work blockchains, Kaspa’s technology allows multiple parallel blocks to coexist rather than discarding them. This innovation increases transaction speed, with a current block generation rate of one per second, with","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/67e5d5f42a8e8b78e9bbee16/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["SSI","SOL.USD.HKCC"],"gpt_icon":0},{"id":"2522532234","title":"Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2522532234","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522532234?lang=en_us&edition=fundamental","pubTime":"2025-03-28 03:46","pubTimestamp":1743104775,"startTime":"0","endTime":"0","summary":"Candel Therapeutics, Inc.  on Wednesday revealed final survival data from a phase 2a trial of CAN-2409 in patients with stage III/IV NSCLC, inadequately responding to Immune Checkpoint Inhibitor  treatment.The median overall survival  was 24.5 months in 46 evaluable patients receiving 2 courses of CAN-2409 and 21.5 months in evaluable patients from cohort 2  that presented with progressive disease at baseline, despite ICI treatment.The company on Wednesday said mOS in patients with progressive disease despite ICI treatment was 9.8-11.8 months in other studies, including those with standard of care of docetaxel chemotherapy.This final analysis included extended follow-up data , with a median follow-up time for the per-protocol population of 32.4 months.Data showed a sizable percentage of patients with survival exceeding 24 months, evidence of a long tail of survival, with 37% of patients with progressive disease despite treatment with ICI alive 2 years after CAN-2409 administration.Biom","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/candel-therapeutics-reports-prolonged-survival-194615613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053666078.USD","LENZ","BK4526","BK4600","BK4585","BK4107","L","CADL","BK4588","BK4170","BK4539","SSI","BK4595","BK4139"],"gpt_icon":1},{"id":"2522093543","title":"Press Release: Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2522093543","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522093543?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:30","pubTimestamp":1743082200,"startTime":"0","endTime":"0","summary":"Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D. Highlights of Annual Results for the Year Ended December 31, 2024. Net profit recorded RMB222.0 million, a significant turnaround from a year ago. Adjusted Non-IFRS net profit recorded RMB314.6 million, a YOY increase of nearly 50.6%.CRO Revenue Growth Improved Significantly Improving in the Second Half of the Year to Sustain a Recovery Momentum Ahead. In 2024, the revenue of the Company's CRO business decreased by approximately 4.0% to RMB810.9 million from RMB844.9 million in the same period of last year, while the corresponding adjusted gross profit decreased by approximately 1.9% to RMB357.1 million from RMB363.8 million in the same period of last year. The decrease in CRO revenue in 2024 as compared to previous years was mainly attributable to the short-term impact of the global biopharmaceutical investment and financing pressure in 202","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","01873","BK1576","SSI"],"gpt_icon":0},{"id":"2522309020","title":"VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2522309020","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522309020?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:31","pubTimestamp":1743078660,"startTime":"0","endTime":"0","summary":"Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing study, which is evaluating the safety and efficacy of the oral formulation of its experimental obesity drug VK2735. Data from this study is expected in the second half of 2025.This study has enrolled around 280 adults who are either obese or overweight and have at least one weight-related co-morbid condition. These patients have been evenly randomized to one of the six dosing arms of the drug or placebo. The study’s primary endpoint is the percent change in body weight from baseline after 13 weeks of treatment.In our opinion, this announcement marks a milestone for the company since the study initiation was declared in January. The rapid enrolment in the study suggests strong demand and interest in VK2735. This aligns with the market expansion for weight loss drugs, fueled by the success of Eli Lilly’s LLY Zepbound and Novo Nordisk’s NVO Wegovy. The quick recruitmen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vktx-finishes-enrolment-mid-stage-123100379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0094547139.USD","LU1280957306.USD","LU1023059063.AUD","LU2602419157.SGD","RHHBY","LU0689472784.USD","03165","LU0820561818.USD","LU0823416689.USD","SGXZ81514606.USD","LU2491050154.USD","LU0965509101.SGD","SG9999013999.USD","LU1732800096.USD","LU0310800379.SGD","VKTX","IE00BVYPNW00.USD","IE00B42XCP33.USD","LU1037948541.HKD","LU0122379950.USD","AMGN","SG9999014898.SGD","LU0882574139.USD","SG9999018865.SGD","SG9999011175.SGD","IE00B19Z3581.USD","SSI","LU1720051017.SGD","LU2129689605.HKD","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","ABBV","LU0198837287.USD","LU0965509283.SGD","IE00BK4W5L77.USD","LU1003077747.HKD","LU0661504455.SGD","LU1988902786.USD","LU0109391861.USD","LU1551013425.SGD","LLY","LU0006306889.USD","BK4532","BK4139","LU1974910355.USD","SG9999018857.SGD","LU1127390331.HKD","BK4533","LU1064131342.USD","LU2087621335.USD"],"gpt_icon":1},{"id":"2522130892","title":"Goldman Sachs’ (GS) Adaptability and Core Strengths Set the Stage for Sustained Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2522130892","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522130892?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:23","pubTimestamp":1743078188,"startTime":"0","endTime":"0","summary":"Nightview Capital, an investment management company that concentrates exclusively on publicly traded equity strategies released its fourth quarter 2024 investor letter.A copy of the letter can be downloaded here. This letter highlights five transformative trends that the firm is observing for 2025 and beyond, along with a review of key companies in the portfolio and how the portfolio is evolving in response to these trends. For more information on the fund’s top picks in 2024, please check its top five holdings.The Goldman Sachs Group, Inc.  is not on our list of30 Most Popular Stocks Among Hedge Funds. As per our database, 81 hedge fund portfolios held The Goldman Sachs Group, Inc.  at the end of the fourth quarter compared to 72 in the third quarter. The Goldman Sach","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/goldman-sachs-gs-adaptability-core-122308970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SSI","IE0034235188.USD","LU2471134796.USD","LU0106831901.USD","BK4550","LU2471134523.USD","LU2750360641.GBP","IE00B19Z3581.USD","LU1868836591.USD","LU0061475181.USD","LU2237443465.HKD","LU2471134952.CNY","LU2471134879.HKD","GS","BK4533","LU1868837136.USD","LU2237443549.SGD","LU0096364046.USD","LU1868836757.USD","LU2750360997.AUD","IE00B19Z3B42.SGD","BK4135","BK4504","BK4127","GSBD","LU2237443622.USD","IE00BFXG1179.USD","IE00BSNM7G36.USD","IE0002270589.USD","LU2237438978.USD","LU1868837300.USD","BK4552","IE0004086264.USD","LU1668664300.SGD","BK4516","LU2237443978.SGD","LU2237443382.USD","BK4588","IE0004091025.USD","LU1791807156.HKD","BK4585","LU1868836914.USD","LU2237443895.HKD"],"gpt_icon":0},{"id":"2522708293","title":"Jeffs’ Brands Announces Completion of Development Stage for Fort’s AI-Based Pest Control App","url":"https://stock-news.laohu8.com/highlight/detail?id=2522708293","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522708293?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:05","pubTimestamp":1743077100,"startTime":"0","endTime":"0","summary":"Application is now undergoing internal testing ahead of launch on Apple App Store and Google Play. Tel Aviv, Israel, March 27, 2025  -- Jeffs' Brands Ltd  , a data-driven e-commerce company operating on the Amazon Marketplace, announced today that further to its previously announcement on November 18, 2024 on the entry into an agreement by its wholly-owned subsidiary, Fort Products Ltd.  with a digital developer, the development phase of its AI-based pest control mobile application has been successfully completed.The innovative app, designed to bring intelligent and accessible pest control solutions directly to users’ smartphones, has now entered its internal testing and fine-tuning stage. This critical phase ensures the application delivers a seamless user experience and meets the highest standards for performance and reliability.Fort is now focused on perfecting the app’s functionality and usability through rigorous internal testing. Once finalized, the application will be submitted ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jeffs-brands-announces-completion-development-120500789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["JFBR","LU2244417387.USD","IE00B19Z8W00.USD","LU2491050071.SGD","LU2362540622.SGD","LU0203201768.USD","LU0708995401.HKD","JFBRW","LU0787776722.HKD","LU1791710400.SGD","USJW.SI","LU2756315318.SGD","LU1059921491.USD","LU0106261372.USD","LU0130102774.USD","LU1145028129.USD","BK4559","LU1064131342.USD","LU0786609619.USD","LU2023250843.SGD","SG9999015945.SGD","SSI","USAW.SI","LU2077746001.SGD","LU2237957811.SGD","LU0198837287.USD","LU2275660780.HKD","LU1069344957.HKD","LU2054465674.USD","LU2764263203.CNY","LU1116320901.HKD","LU1235294995.USD","LU1035773651.USD","LU0187121727.USD","IE00B1XK9C88.USD","LU1046421795.USD","BK4538","LU0056508442.USD","LU1823568750.SGD","LU1791710582.SGD","SG9999001077.SGD","LU0965509010.AUD","BK4579","IE0009356076.USD","LU2097344431.USD","SG9999000418.SGD","LU1718418525.SGD","IE0009G5SDU7.USD"],"gpt_icon":1},{"id":"2522365312","title":"Senate Vote Sets Stage for President Trump to Sign Bill Ending IRS DeFi Broker Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2522365312","media":"BE[IN]CRYPTO","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522365312?lang=en_us&edition=fundamental","pubTime":"2025-03-27 13:24","pubTimestamp":1743053090,"startTime":"0","endTime":"0","summary":"The US Senate passed a resolution to repeal the IRS DeFi broker rule, clearing the way for less regulation and more innovation in DeFi.President Trump is expected to sign the bill, which could likely become law by the end of the week, marking a win for the cryptocurrency industry.A coalition, including top crypto firms, is urging Congress to address the DOJ’s misinterpretation of money transmission laws, potentially threatening blockchain development.The US Senate has voted in favor of a motion to repeal an IRS rule targeting decentralized finance  platforms. The motion now heads to President Donald Trump’s desk for his anticipated signature.According to the latest reports, the resolution is close to becoming law, potentially by the end of this week.On March 26, the Senate voted 70-28 to pass H.J. Res. 25, introduced by Senator Ted Cruz and Representative Mike Carey. This vote marks the second time this month that the resolution has passed, following a 70-27 vote on March 4.Specificall","market":"us","thumbnail":"https://beincrypto.com/wp-content/uploads/2023/03/bic_United-States-_neutral_3-850x478.png","type":0,"news_type":0,"thumbnails":["https://beincrypto.com/wp-content/uploads/2023/03/bic_United-States-_neutral_3-850x478.png"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://beincrypto.com/senate-repeals-irs-rule-defi/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"beincrypto_highlight","symbols":["BK4205","SSI","BK4233","IRS"],"gpt_icon":0},{"id":"2522527053","title":"Social Security says some applicants are exempt from in-person office visits","url":"https://stock-news.laohu8.com/highlight/detail?id=2522527053","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522527053?lang=en_us&edition=fundamental","pubTime":"2025-03-27 06:48","pubTimestamp":1743029280,"startTime":"0","endTime":"0","summary":"Applicants for Medicare, disability and SSI can complete claims over the phone. The Social Security Administration on Wednesday said it would not require all people applying for Social Security Disability Insurance, Medicare or Supplemental Security Income to come into an office to verify their identity in person.Under the new rules, individuals applying for Social Security Disability Insurance , Medicare or Supplemental Security Income  who are not able to use a \"my Social Security\" online account can complete their claim entirely over the telephone without the need to come into an office.This is a reversal for the Social Security Administration, which earlier this month said people seeking assistance with identity verification on benefit claims and direct-deposit changes would need to complete claims using their personal online account or would have to visit a Social Security office in person to prove their identity.The so-called Department of Government Efficiency - or DOGE - has be","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0689472784.USD","LU2602419157.SGD","SG9999015945.SGD","BK4598","LU0861579265.USD","LU1861220033.SGD","BK4581","LU0175139822.USD","BK4534","BK4574","BK4604","LU1551013425.SGD","LU0069063385.USD","LU1037948541.HKD","LU1435385759.SGD","LU1548497426.USD","LU2125909759.SGD","LU2471134523.USD","LU2756315318.SGD","BK4527","IE00BJLML261.HKD","LU0130103400.USD","LU0943347566.SGD","LU0289960550.SGD","LU2250418816.HKD","SG9999015952.SGD","LU2750360641.GBP","SSI","LU1366192091.USD","BK4585","LU0316494557.USD","LU2360107168.USD","LU1934455194.USD","BK4511","LU0511384066.AUD","LU0820561909.HKD","LU1839511570.USD","LU0345770993.USD","LU2087621335.USD","SG9999015986.USD","TSYW.SI","LU0097036916.USD","LU0130102774.USD","LU0234570918.USD","LU1066053197.SGD","SG9999015978.USD","LU0823411888.USD","LU2023250330.USD","FI"],"gpt_icon":1},{"id":"2522383583","title":"Nvidia's CPO Reveal Sets Stage for Wave of Optical Tech Announcements","url":"https://stock-news.laohu8.com/highlight/detail?id=2522383583","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522383583?lang=en_us&edition=fundamental","pubTime":"2025-03-27 00:34","pubTimestamp":1743006878,"startTime":"0","endTime":"0","summary":"J.P. Morgan expects more tech companies to announce co-packaged optics  plans following Nvidia's  reveal at GTC 2025. The bank is watching for new developments at the upcoming Optical Fiber Communications Conference, set to run from March 30 to April 3 in San Francisco.GuruFocus has detected 3 Warning Signs with NVDA.At GTC, Nvidia introduced a silicon photonics-based switch using CPO to support faster, short-range data links in AI data centers. CEO Jensen Huang said the company had developed the world's first 1.6 terabit per second CPO, using a micro ring resonator modulator and advanced TSMC  chip technology.J.P. Morgan analysts, led by Samik Chatterjee, noted in a client briefing that companies like Broadcom , Marvell , and potentially Cisco  may follow Nvidia's lead with similar announcements or product demos at OFC.Suppliers involved in Nvidia's optical efforts include Lumentum , Coherent , Corning , and Fabrinet , which provide key components for its photonics infrastructure.Inve","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvidias-cpo-reveal-sets-stage-163438648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["3NVD.UK","NVDA","USJW.SI","BK4614","NVDS","LU0731783394.SGD","LU1599440770.SGD","2NVD.UK","LU2237443978.SGD","GLW","COHR","MNQmain","IE00BJTD4V19.USD","OCC","NVD2.UK","NVDU","SNVD.UK","LU1035775433.USD","PSQ","NVDS.UK","FN","NQmain","QID","USAW.SI","NVDX","SQQQ","LITE","03145","TQQQ","TSYW.SI","LU0267386448.USD","CSCO",".IXIC","IE00B1XK9C88.USD","SSI","LU0106261612.USD","QLD","NVD3.UK","NVDD","NVIW.SI","LU1069344957.HKD","BK4551","BK4526","NVD","NVDY"],"gpt_icon":1},{"id":"2522133882","title":"A New Chapter Awaits – Take Centre Stage in F1® 25; An Epic Formula 1® Blockbuster","url":"https://stock-news.laohu8.com/highlight/detail?id=2522133882","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522133882?lang=en_us&edition=fundamental","pubTime":"2025-03-27 00:06","pubTimestamp":1743005160,"startTime":"0","endTime":"0","summary":"Lewis Hamilton Confirmed as F1 25 Iconic Edition Cover Star. Popular game mode, My Team receives its first significant overhaul with players calling the shots as the owner of their F1 team. Take on new responsibilities before getting behind the wheel as either of the team’s drivers. On track, F1 25 continues to innovate through the power of its EGO engine. Enabling increased circuit authenticity made possible through LIDAR technology, several tracks and their surroundings are transformed with a more realistic look and feel. More details on the gameplay features and innovations will be revealed shortly through the F1 25 Deep Dive series.Players who pre-order* the digital-exclusive F1 25 Iconic Edition will receive a multitude of perks linked to cover star Lewis Hamilton and the film F1, alongside a selection of instantly available 2025 season liveries for use in F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chapter-awaits-centre-stage-f1-160600200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SSI","BK4085","BK4532","BK4577","LU2506951958.HKD","LU2506952097.USD","LU2247934214.USD","BK4585","LU1430594728.SGD","LU2506951875.HKD","LU1585245621.USD","LU2506952170.USD","BK4588","LU0950375773.USD","LU0823417737.USD","EA","LU0823417653.USD","LU0006061336.USD","BK4533"],"gpt_icon":0},{"id":"2522880492","title":"SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2522880492","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522880492?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:43","pubTimestamp":1742989380,"startTime":"0","endTime":"0","summary":"Shares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, simufilam, failed to meet the prespecified co-primary endpoints in the second late-stage study for Alzheimer’s disease . Simufilam is SAVA’s proprietary, investigational oral small molecule that targets the filamin A protein.Cassava released top-line results from the phase III REFOCUS-ALZ study, which evaluated simufilam in patients with mild-to-moderate AD. Treatment with the drug failed to achieve a significant reduction in cognitive and functional decline in AD patients when compared to placebo over 76 weeks, as assessed by the ADAS-COG12 and ADCS-ADL scales. The study also failed to meet any pre-specified secondary and exploratory biomarker endpoints.The REFOCUS-ALZ study had enrolled 1,125 AD patients who were randomized equally to receive either a twice-daily, oral dose of simufilam  or placebo for 76 weeks. The candidate, however, demonstrated an acceptable safe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sava-stock-down-alzheimers-drug-114300226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4581","LU0109394709.USD","LU0203202063.USD","LU2461242641.AUD","BIIB","LU1917777945.USD","LU1280957306.USD","IE0004445239.USD","SG9999001176.SGD","LU1057294990.SGD","LU1291159041.SGD","LU1093756325.SGD","SSI","LU0466842654.USD","LU1988902786.USD","SGXZ51526630.SGD","LU2112291526.USD","LU1868837136.USD","IE00BJJMRZ35.SGD","IE00BK4W5M84.HKD","SGXZ81514606.USD","LU1989771016.USD","SAVA","BK4547","IE00B1BXHZ80.USD","SG9999014914.USD","SG9999013999.USD","LU0006306889.USD","BK4007","BK4532","LU2265009873.SGD","LU0096364046.USD","LU2360106947.USD","SG9999015986.USD","LU0820561909.HKD","LU2491050071.SGD","GILD","SG9999001176.USD","SG9999017495.SGD","BK4583","LU0094547139.USD","IE00BJLML261.HKD","LU0198837287.USD","LU0640476718.USD","LLY","LU1839511570.USD","LU0114720955.EUR","BK4566","SAVAW","LU1093756168.USD","LU2106854487.HKD"],"gpt_icon":0},{"id":"2522683545","title":"Palestinians Stage Rare Protest Against Hamas in Gaza -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2522683545","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522683545?lang=en_us&edition=fundamental","pubTime":"2025-03-26 05:14","pubTimestamp":1742937240,"startTime":"0","endTime":"0","summary":"In a rare protest against Hamas, hundreds of Palestinians took the streets in a northern Gazan town on Tuesday, venting their frustrations openly for the first time since the start of the 17-month war that has left much of the enclave in ruins.\"Out, Out, Out, Hamas out,\" the crowd of mostly young men chanted, some waving white flags, in a video posted on social media.The demonstrations began spontaneously in Beit Lahia during a funeral and spread to the nearby Jabalia refugee camp. By nightfall, Palestinians in Khan Younis, in southern Gaza, had also taken to the streets to denounce Hamas. While their size was limited, they were a notable sign of discontent with Hamas, which led the Oct. 7, 2023, attacks that left around 1,200 dead, another roughly 250 taken hostage and sparked the war that has devastated Gaza.Israel shattered a two-month cease-fire last week by returning to fighting with waves of airstrikes and incursions by ground troops, saying Hamas had failed to release hostages r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SSI"],"gpt_icon":0},{"id":"2522833781","title":"Ripple to Retain $75 Million From SEC As the XRP Lawsuit Enters Final Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2522833781","media":"BE[IN]CRYPTO","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522833781?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:03","pubTimestamp":1742933003,"startTime":"0","endTime":"0","summary":"Ripple now has the ability to sell XRP tokens to institutional investors, potentially boosting liquidity and partnerships.Despite the legal win, XRP's price has remained stagnant, likely impacted by broader bearish market trends.Ripple’s Chief Legal Officer announced today that its XRP lawsuit with the SEC is approaching the final legal phase. The SEC will keep $50 million from the previous $125 million fine and return the rest to Ripple.Most importantly, Ripple will likely be able to offer XRP tokens to institutional investors, which could impact market liquidity and ETF approval odds.Another critical ruling in the 2024 decision was that Ripple could not sell XRP to institutional investors. The firm had reportedly been negotiating with the SEC to drop this mandate for weeks.Over the past week, the XRP community has expressed some concerns regarding the extremely low DEX trading volume on the network. Yet, Ripple’s new progress with the SEC may create plenty of opportunities to foster ","market":"nz","thumbnail":"https://beincrypto.com/wp-content/uploads/2023/06/BIC_Ripple-covers-850x478.png","type":0,"news_type":0,"thumbnails":["https://beincrypto.com/wp-content/uploads/2023/06/BIC_Ripple-covers-850x478.png"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://beincrypto.com/sec-return-fine-in-ripple-xrp-lawsuit/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"beincrypto_highlight","symbols":["XRP.USD.CC","SSI"],"gpt_icon":0},{"id":"2522670794","title":"Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2522670794","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522670794?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:05","pubTimestamp":1742846700,"startTime":"0","endTime":"0","summary":"Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July 2024Signed strategic partner and investor, Bio-Rad LaboratoriesFully funded cli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3048296/0/en/Oncocyte-Reports-Successful-2024-Sets-Stage-for-2025-Catalysts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SSI","BK4179","BK4585","BK4121","LU1481600234.SGD","LU1481599808.USD","BIO","AMR","BK4006","BK4588","IP","LU1169589451.USD","LU1487256676.USD","NGS","LU2463526074.USD","LU1169590202.USD","BK4136","NPV"],"gpt_icon":0},{"id":"2521277627","title":"Can-Fite BioPharma Begins Late-Stage Study of Prospective Psoriasis Medication","url":"https://stock-news.laohu8.com/highlight/detail?id=2521277627","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521277627?lang=en_us&edition=fundamental","pubTime":"2025-03-24 22:08","pubTimestamp":1742825324,"startTime":"0","endTime":"0","summary":"Can-Fite BioPharma  said Monday it has initiated a phase 3 study of its Piclidenoson drug candidate in patients with moderate to severe plaque psoriasis, with enrollment starting in Europe and in the US with Canada to follow.The co-primary objectives of the study are the proportion of patients whose psoriasis is reduced in size and severity by 75% or more and the proportion who achieve a Static Physician's Global Assessment score of either 0 or 1 after 16 weeks, the company said.The US Food and Drug Administration encouraged the company to enroll adolescent patients due to the strong safety profile of the drug  demonstrated during development and earlier trials, Can-Fite said.Can-Fite is expecting to file a new drug application for Piclidenoson with the FDA and a marketing authorization plan with the European Medicines Agency on the successful conclusion of the trial, the company said.Price: 1.66, Change: +0.06, Percent Change: +3.94","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SSI","CANF","BK4139"],"gpt_icon":0},{"id":"2521474177","title":"Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2521474177","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521474177?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"BOSTON, March  24, 2025  (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047808/0/en/Praxis-Precision-Medicines-to-Present-on-Late-Stage-Programs-across-Epilepsy-and-Movement-Disorders-at-the-American-Academy-of-Neurology-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","MDCO","AFG","SSI"],"gpt_icon":0}],"pageSize":16,"totalPage":13,"pageCount":1,"totalSize":200}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SSI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-11-21","symbol":"SSI","fiscalQuarterEnding":"2019/10","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1574312400000,"reportTimeType":"pre","actualEps":-0.15},{"date":"2019-08-22","symbol":"SSI","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/07","expectedEps":null,"defaultRemindTime":1566460800000,"name":null,"time":"Pre-Market","dateTimestamp":1566446400000,"actualEps":-0.6},{"market":"US","date":"2019-05-23","symbol":"SSI","fiscalQuarterEnding":"2019/04","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1558584000000,"reportTimeType":"pre","actualEps":-1.67},{"market":"US","date":"2019-03-07","symbol":"SSI","fiscalQuarterEnding":"2019/01","expectedEps":0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551934800000,"reportTimeType":"pre","actualEps":0.25},{"market":"US","date":"2018-12-03","symbol":"SSI","amount":0.05,"name":"Stage Stores Inc","currency":"USD","type":"dividend","dateTimestamp":1543813200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SSI\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-24","recordDate":null,"paymentDate":null,"value":0.15,"currency":"USD"},{"executeDate":"2017-05-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-08-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-11-27","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2018-03-05","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SSI\",market:\"US\",delay:false,,,undefined,":{}}}